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Abstract-Studies
were performed to determine the effects of an immunopotentiating agent, lentinan, on the hepatic drug-metabolizing enzymes in mice. Lentinan was injected twice a day for two days, and the enzyme activities were determined 12 hr after the last injection of lentinan.
A lentinan dose of over 0.25 mg/kg was required to cause a significant decrease (20-40%) in the hepatic microsomal aminopyrine N-demethylase and aniline hydroxylase activities. The loss of drug-metabolizing activity by the treatment with lentinan agreed with the loss of cytochrome P-450 content in many cases.
Strain and substrate differences concerning the effect of lentinan on the metabolism of drug were also observed.
That is to say, the loss of cytochrome P-450 content by the treatment with lentinan was observed in the ddY, C57BL/6 and BDF1 strain mice, but was not observed in the DBA/2, C3H/He and C57BL/10 strain mice. The decrease in the activities of 7-ethoxycoumarin 0 deethylase and biphenyl 2-hydroxylase by the treatment with lentinan was con siderably less than that of aminopyrine N-demethylase and aniline hydroxylase in ddY mice.
As recent trends in cancer treatment, immunotherapy is employed alone or in combination with chemotherapy and/or other methods.
Furthermore, many investigators reported the use of whole microorganisms and its components prepared or extracted from microorganisms as immunotherapeutic agents.
Some agents such as Bacillus Calmette-Guerin (BCG), Corynebacterium parvum, OK-432 (a Streptococcus pre paration), bacterial endotoxin and levamisole showed potent immunotherapeutic actions on cancer in preclinical and clinical studies, but they exhibited some side effects in patients or experimental animals (1-5).
Lentinan, a polysaccharide obtained from Lentinus edodes (Berk.) SING, shows anti tumor activity in mice and rats bearing syngeneic and autochthonous tumors and in patients with malignant pleurisy and lung cancer (6-9). Lentinan has been developed as an immunotherapeutic agent for clinical use.
It is well known that the metabolism of a large number of drugs and foreign compounds is catalyzed by the hepatic microsomal drug metabolizing enzyme system that consists of a flavoprotein such as NADPH-cytochrome c reductase and cytochrome P-450.
Specific decrease in the cytochrome P-450 content have recently been demonstrated in animals treated with an immunotherapeutic agent (4, 5, 10). Accordingly, it is possible that the phar macokinetics of drugs will be altered in animals treated with an immunotherapeutic agent. These results might be important in the immunochemotherapy of cancer because chemotherapeutic agents are metabolized to active or inert metabolites by the hepatic microsomal mixed function oxidase system.
We therefore investigated the possibility that lentinan affects the metabolism of other drugs by means of in vitro assays with model substrates for the mixed function oxidase of hepatic microsomes.
Materials and Methods
Animals: Male ddY strain mice purchased from Shizuoka Laboratory Animal Center were mainly used through this study, but male DBA/2, C57BL/6, BDF1, C31-1/He and C57BL/10 strain mice were used in some experiments. Animals weighing 22-24 g each, except when indicated otherwise, were allowed to acclimatize to our facilities at least for 3 days before experiment and were fed water and a standard diet.
aniline hydroxylase activities were determined by the method of Nash (14) Effect of lentinan on the sleeping time induced by pentobarbital or ketamine: The effect of pretreatment with lentinan on the sleeping time induced by pentobarbital or ketamine is shown in Fig. 1 . Prolongation of the pentobarbital or ketamine-sleeping time was observed when the mice were adminis tered lentinan at a dose of 1 or 4 mg/kg, respectively. Apparently, lentinan prolonged the pentobarbital or ketamine-sleeping time according to the number of administrations. That is to say, the effect of 1 or 4 mg/kg of lentinan twice a day for two days was stronger than that of the same dose of lentinan twice every 12 hr.
Effect of lentinan on the microsomal metabolism of aminopyrine and aniline and the content of cytochrome P-450: The effects of pretreatment with lentinan of the microsomal metabolism of aminopyrine and aniline and the content of cytochrome P-450 in liver are shown in Fig. 2 . A significant reduction in the hepatic microsomal content of cytochrome P-450 was observed when the mice were administered lentinan at a dose of 0.25, 0.5, 1.0 or 4 mg/kg, respectively, twice a day for two days. In these cases, the depression rate was 10%, 13%, 17% and 21 %, respectively, when compared to the control value. A similar depression of the activity of aminopyrine N-demethylase was observed dose-dependently by the treatment with lentinan.
However, the activity of aniline hydroxylase was not inhibited dose dependently by lentinan. Fig. 1 . Effect of lentinar, on the sleeping time induced by pentobarbital or ketamine. A group consisting of 8-10 ddY mice was used. Twelve or 24 hr after the last injection of lentinan, pentobarbital (50 mg/ kg, i.p.) or ketamine (150 mg/kg, i.p.) was injected to mice and the sleeping time was measured. Control animals were treated with physiological saline, and then hypnotic drugs were injected. Results are expressed as the amplitude to the control value. Symbols and control value are: 0 Pentobarbital sleeping time, 35.4±2.18 min; = Ketamine sleeping time, 32.1±4.18 min. a) Lertinan was given once a day for two days. Mice were sacrificed 24 hr after the last administration. u) Lentinan was given twice a day. Mice were sacrificed 12 hr after the last administration. 0 Lentinan was given twice a day for two days. Mice were sacrificed 12 hr after the last administration.
Strain difference of the effect of lentinan on the hepatic microsomal cytochrome P 450 content: The effect of pretreatment with 1 mg/kg of lentinan twice a day for two days on the microsomal cytochrome P-450 content was studied using several strains of mice. Difference of depression of the hepatic microsomal cytochrome P-450 by lentinan was observed conspicuously in several strains of mice such as ddY, DBA/2, C57BL/ 6, BDF1, C3H/He and C57BL/10. The significant reduction of cytochrome P-450 content was obtained in ddY, C57BL/6 and BDF1 strains as compared with the control value.
Effects of lentinan and BCG on the mixed function oxidase system: The effects of lentinan and BCG on some hepatic parameters and enzymes of the mixed function oxidase system are summarized in Table 2 .
Significant reductions of cytochrome P Fig. 2 . Effect of lentinan on the microsomal metabolism of aminopyrine and aniline arid the content of cytochrome P-450 in liver. Lentinan was given intraperitoneally to ddY mice twice a day for two days. Control animals were similarly treated with physiological saline. Results are expressed as a percentage calculated from specific activities ±S.E. of 4-8 determinations compared to the control value. Significant difference from the control value are indicated as *(P ;0.05) and **(P<0.01 ). Symbols: = Cytochrome P-450 content, Aminopyrine N-demethylase, i~ , Aniline hydroxylase. and C57BL/10, 0.77±0.089 (nmol/mg of protein). Significant differences from the control value are indicated as **(P<0.01). and aminopyrine N-demethylase, aniline hydroxylse and pentobarbital oxidase activities were observed by the intraperito neal administration of 1 mg/kg of lentinan twice a day for two days. In vitro effect of lentinan on the hepatic drug metabolizing enzymes:
The direct effect of lentinan on the activities of aminopyrine N-demethylase and aniline hydroxylase was examined by addition of lentinan (50 gig in 0.1 ml) to 0.9 ml of the incubation mixture containing the hepatic microsomes of ddY mice in vitro. The final concentration of lentinan in the incubation mixture was 5 X 10-5 g/ml. No change was observed on the activities of both enzymes with or without the addition of lentinan directly.
Effect of lentinan on the apparent kinetic constant of hepatic microsomal aminopyrine N-demethylase:
The effect of lentinan on the enzyme kinetic parameters of the amino pyrine N-demethylase was studied using 1, 3 and 5 mM of aminopyrine.
Lentinan was administered intraperitoneally at a dose of 1 mg/kg twice a day for two days.
The Lineweaver-Burk plot of aminopyrine N-demethylase in the hepatic microsomes from untreated and lentinan-treated mice indicated a non-competitive inhibition. We have demonstrated that the adminis tration of lentinan, an immunotherapeutic agent, causes a marked depression of the drug-metabolizing enzymes in the liver of mice, the depression being observed dose dependently at over 0.25 mg/kg of lentinan.
The minimal effective intraperitoneal dose of lentinan in mice for antitumor therapy is 0.5 mg/kg, and Chihara et al. (6) have reported that an intraperitoneal injection of lentinan (0.5-10 mg/kg) caused a dose dependent antitumor activity with no evidence of toxicity. Thus the therapeutic dose of lentinan in mice also inhibits the hepatic drug-metabolizing system. Also, there is a relationship between the increase in lipid peroxides on the microsomal membrane and the concomitant decrease in the levels of cytochrome P-450 caused by the administration of certain foreign compounds. Furtheremore, a strong decline in the ability of microsomes to oxidize aminopyrine and aniline is due to the degradation of cyto chromre P-450 heme (21), the blockade of electron current from NADPH-cytochrome c reductase (22, 23) , and the destruction of lipid which is essential for drug-metabolizing enzyme activity (24). The present results demonstrated that lentinan did not increase the hepatic lipid peroxidation.
Furthermore, the reductions of aminopyrine N-demethylase, aniline hydroxylase and pen tobarbital oxidase activities were observed by the administration of lentinan, when the activities were expressed in nmol of metabolite formed per mg of protein. However, if the activities were expressed in nmol of metabolite formed per nmol of cytochrome P-450 per 20 or 60 min, there were no significant difference between lentinan-treated mice and control mice. These results lead to the conclusion that the inhibition of the hepatic drug-me tabolizing enzyme system by the adminis tration of lentinan was mainly based on the decrease in cytochrome P-450 content, but not on the increase in lipid peroxidation and the decrease in NADPH-cytochrome c reductase.
Previously, we have been studied the effect of immunopotentiating agents, for example OK-432, LPS or M. butyricum, on the hepatic drug-metabolizing enzymes in mice (5, 25) . The significant reduction of the hepatic drug-metabolizing enzymes activities was observed by the treatment with these immunopotentiating agents.
On the other hand, the effect of BCG on the hepatic drug metabolizing enzymes was similar to that of the immunopotentiating agents mentioned above. Namely, the treatment with BCG decreased the contents of cytochrome P-450 and cytochrome b5 and the activities of aminopyrine N-demethylase, aniline hydroxy lase and biphenyl 2-hydroxylase ( Table 2 ). The effect of lentinan on the hepatic drug metabolizing enzymes was weaker than that of BCG or these immunopotentiating agents. Cytochrome P-450 is the terminal oxidase in the drug-metabolizing enzyme system. Therefore, it is reasonable to assume that the inhibition of drug-metabolizing enzymes by lentinan may be due to the decrease in the cytochrome P-450 content of hepatic microsomes.
A strain difference of the effect of lentinan on the cytochrome P-450 content was also observed. In the ddY, C57BL/6, and BDF1 strains, the loss of cytochrome P-450 content was observed significantly by the treatment with lentinan. However, cytochrome P-450 content was not reduced by the treatment with lentinan in the C3H/He, C57BL/10 and DBA/2 strains that are non-sensitive to lentinan in experimental cancer therapy and less responsible to aryl hydrocarbon hy droxylase.
Moreover, lentinan caused the decrease in the activity of hepatic drug metabolizing enzyme. Among the drug metabolizing enzymes, the decrease in the activities of 7-ethoxycoumarin O-deethylase and biphenyl 2-hydroxylase was less than that in the activities of aminopyrine N demethylase, aniline hydroxylase and pen tobarbital oxidase. It may also occur that one or a few types of the cytochrome P-450's was lost preferentially after the administration of lentinan. Impairment of the drug-metabolizing enzyme system by lentinan was not due to the systemic toxicity of lentinan. Also, no significant differences between control mice and lentinan-treated mice were found in body weight, liver weight and microsomal protein content per g of liver.
The enzyme substrate studies on hepatic microsomal preparations of control mice and lentinan-treated mice pointed out that the administration of lentinan lowered by one quarter the maximal velocity of the mono oxygenase reactions, as observed by the Lineweaver-Burk plot. Thus, lentinan exerts its depressive effect on drug-metabolizing enzyme activities through an in vivo mecha nism which results in lowering the levels of microsomal cytochrome P-450 by decreasing the synthesis of these proteins or by ac celeration of their degradation.
A significant decrease in the cytochrome P-450 content of hepatic microsomes was observed after the administration of lentinan, but no significant alteration by lentinan was observed on the activities of NADPH cytochrome c reductase and NADH ferricyanide reductase and cytochrome b5 content.
NADPH-cytochrome c reductase is known to be a rate-limiting enzyme of the hepatic microsomal drug-metabolizing enzyme system (22) and is also known to catalyze microsomal lipid peroxidation (23).
Recently, some investigators reported that immunotherapeutic agents such as bacterial endotoxin, OK-432 and PS-K inhibited the activity of hepatic 6-aminolevulinic acid synthetase, a rate-limiting enzyme of heme biosynthesis, and increase the activity of hepatic heme oxygenase, a heme-degrading enzyme (25, 26) . These suggest that the decrease in the microsomal mixed function oxidase activity and the content of cyto chrome P-450 result from the inhibition of 6-aminolevulinic acid synthetase and in crease in heme oxygenase activity. The results suggest that after the treatment with lentinan, the same phenomena
